Ampio Publication Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation
|
ENGLEWOOD, Colo., Oct. 8, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc., (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the publication of a scientific manuscript on Ampion™ effects on peripheral blood monocytes ("PBMC") in a preprint report (Ampion suppresses cytokine release by modulating select inflammatory transcription factor activity in stimulated PBMC, DOI: https://doi.org/10.21203/rs.3.rs-86515/v1).
In this report, evidence is provided that Ampion reduces pro-inflammatory cytokine release by activating the immunoregulatory transcription factors PPARγ and AhR. In addition, data indicates that Ampion suppresses NF-κB and STAT1α pro-inflammatory pathways, suggesting that Ampion acts through these mechanisms to decrease pro-inflammatory transcription factor activity and subsequent inflammatory cytokine production. This publication adds to the growing evidence of the important anti-inflammatory activities of Ampion in various inflammation related conditions, including the dysregulated immune response observed in severe COVID-19 infected patients. A recurring theme across all clinical trials with Ampion, including our recent Phase I trial for intravenous ("IV") Ampion treatment for COVID-19 patients, is that this anti-inflammatory biologic has been safe and well-tolerated with no serious drug related adverse events. https://ampiopharma.com/news/ampio-reports-positive-results-in-early-trial-for-iv-ampion-treatment-in-covid-19-patients/ About Inflammatory Diseases Inflammation refers to a biological response to stimuli interpreted by the body to have a potentially harmful effect. Inflammatory disorders that result in a dysregulated immune response by attacking the body's own cells or tissues may result in chronic pain, tissue damage and loss of function. Inflammation plays a major role in many disease processes including allergy, asthma, autoimmune disorders such as hepatitis, inflammatory bowel disease, transplant rejection and more. About Ampio Pharmaceutical Forward-Looking Statements Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application ("BLA"), the ability of Ampio to enter into partnering arrangements, clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise. Company Contact
SOURCE Ampio Pharmaceuticals, Inc. |
||
Company Codes: AMEX:AMPE |
View original content to download multimedia: